Oliver Hantschel

15PUBLICATIONS
70CO-AUTHORS
Haematological tumoursBiomolecular modelling and designMolecular targetsBiologically active moleculesTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|May 22, 2026
From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia.

|Dec 23, 2024
Development of mirror-image monobodies targeting the oncogenic BCR::ABL1 kinase.

Nina Schmidt, Amit Kumar, Lukas Korf

|Jun 15, 2024
The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib.

Inga B Leske, Oliver Hantschel

|Apr 21, 2024
BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib.

Ariel Leyte-Vidal, Diego Garrido Ruiz, RosaAnna DeFilippis

|Feb 16, 2024
The druggability of SH2 domains unmasked.

Oliver Hantschel

|Aug 17, 2022
Synthesis of the l- and d-SH2 domain of the leukaemia oncogene Bcr-Abl.

Nina Schmidt, Frank Abendroth, Olalla Vázquez

Pageof 3

Frequent Collaborators

2 joint publications

Shohei Koide

2 joint publications

Inga B Leske

2 joint publications

Florence Pojer

2 joint publications

Nina Schmidt